Sigma Pharmaceuticals

Sigma Healthcare is a pharmaceutical wholesale and distribution business in Australia, delivering to pharmacies Australia wide.Co.'s pharmacy-led network includes over 700 retail brand members representing the brands Amcal, Guardian, PharmaSave, Chemist King and Discount Drugstores. Co. also manages and promotes a range of Over the Counter private label products made available to brand member customers, as well as a generic range of private label products under the Pharmacy Care range. In addition, Co., through its subsidiary, Central Healthcare Services, has a presence in the hospital pharmaceutical distribution market.
  • TickerSIG
  • ISINAU000000SIG5
  • ExchangeAustralian Securities Exchange
  • SectorFood & Drug Retailers
  • CountryAustralia

Analysts

SIGMA HEALTHCARE LTD. reduced its risk exposure resulting in an upgrade to Slightly Positive

SIGMA HEALTHCARE LTD. (AU), a company active in the Drug Retailers industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date March 13, 2020, the closing price was AUD 0.52 and its potential was estimated at AUD 0.68.

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

1 director sold

A director at Sigma Healthcare Limited sold 4,543,034 shares at 0.666AUD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The na...

Brian Han

Morningstar | Sigma Puts on a Stoic Front After a Year of Living Dangerously

It was important for Sigma to deliver a result and an outlook inspiring confidence among shareholders, with some still smarting over its decision to spurn Australian Pharmaceutical Industries', or API's, merger proposal. A fiscal 2019 underlying EBIT of AUD 76 million (down 16%) was a good start, compared with the AUD 75 million guidance which was also our estimate. Granted, EBITDA/cash conversion was low at 35%, as cash conversion cycle increased by 4 days to 36. This, combined with the capital expenditure program on distribution centre upgrades (around AUD 100 million), pushed net debt to A...

Brian Han

Morningstar | Sigma Aims for Cost Efficiencies via Project Pivot

Sigma Pharmaceuticals is one of Australia's three pharmaceutical wholesalers. Historically, the company has impressed on several fronts, displaying a capacity to grow both organically and by acquisition. However, in 2005, Sigma merged with then rapidly growing generic pharmaceutical supplier Arrow Pharmaceuticals, which proved disappointing and led to a significant write-down in the value of related goodwill. Subsequently, in 2010, Sigma agreed to sell its manufacturing and generics business to Aspen Pharmacare, in order to reduce debt levels. Management initiatives have delivered significant ...

1 director sold

A director at Sigma Healthcare Limited sold 4,543,034 shares at 0.666AUD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The na...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior